HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a price target of $21.
June 12, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on PDS Biotechnology and maintained a price target of $21.
The reiteration of a Buy rating and maintenance of a $21 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100